Serum phosphorylated neurofilament heavy-chain levels reflect phenotypic heterogeneity and are an independent predictor of survival in motor neuron disease.
ALS
Amyotrophic lateral sclerosis
Biomarkers
C9orf72
FTD
Journal
Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
received:
23
01
2020
accepted:
13
04
2020
revised:
10
04
2020
pubmed:
20
4
2020
medline:
22
6
2021
entrez:
20
4
2020
Statut:
ppublish
Résumé
To investigate the prognostic role and the major determinants of serum phosphorylated neurofilament heavy -chain (pNfH) concentration across a large cohort of motor neuron disease (MND) phenotypes. Enzyme-linked immunosorbent assay (ELISA) was used to measure serum pNfH concentration in 219 MND patients consecutively enrolled in our tertiary MND clinic. A multifactorial analysis was carried out to investigate the major clinical determinants of serum pNfH. Kaplan-Meier survival curves and Cox regression analysis were performed to explore the prognostic value of serum pNfH. Serum pNfH levels were not homogenous among MND phenotypes; higher concentrations in pyramidal, bulbar, and classic phenotypes were observed. C9orf72-MND exhibited higher pNfH concentrations compared to non-C9orf72 MND. Multiple linear regression analysis revealed mean MEP/cMAP and disease progression rate as the two major predictors of serum pNfH levels (R
Identifiants
pubmed: 32306171
doi: 10.1007/s00415-020-09838-9
pii: 10.1007/s00415-020-09838-9
pmc: PMC7166001
doi:
Substances chimiques
Biomarkers
0
Neurofilament Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2272-2280Subventions
Organisme : Italian Ministry of Health
ID : #RF-2011-02351193
Références
Riva N, Agosta F, Lunetta C, Filippi M, Quattrini A (2016) Recent advances in amyotrophic lateral sclerosis. J Neurol 263(6):1241–1254. https://doi.org/10.1007/s00415-016-8091-6
doi: 10.1007/s00415-016-8091-6
pubmed: 27025851
pmcid: 4893385
Hardiman O, Al-Chalabi A, Chio A, Corr EM, Logroscino G, Robberecht W, Shaw PJ, Simmons Z, van den Berg LH (2017) Amyotrophic lateral sclerosis. Nat Rev Dis Primers 3:17085
doi: 10.1038/nrdp.2017.85
Chio A, Calvo A, Moglia C, Mazzini L, Mora G, Group Ps (2011) Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population based study. J Neurol Neurosurg Psychiatry 82(7):740–746. https://doi.org/10.1136/jnnp.2010.235952
doi: 10.1136/jnnp.2010.235952
pubmed: 21402743
Montuschi A, Iazzolino B, Calvo A, Moglia C, Lopiano L, Restagno G, Brunetti M, Ossola I, Lo Presti A, Cammarosano S, Canosa A, Chio A (2015) Cognitive correlates in amyotrophic lateral sclerosis: a population-based study in Italy. J Neurol Neurosurg Psychiatry 86(2):168–173. https://doi.org/10.1136/jnnp-2013-307223
doi: 10.1136/jnnp-2013-307223
pubmed: 24769471
McCann EP, Williams KL, Fifita JA, Tarr IS, O'Connor J, Rowe DB, Nicholson GA, Blair IP (2017) The genotype-phenotype landscape of familial amyotrophic lateral sclerosis in Australia. Clin Genet 92(3):259–266. https://doi.org/10.1111/cge.12973
doi: 10.1111/cge.12973
pubmed: 28105640
Umoh ME, Fournier C, Li Y, Polak M, Shaw L, Landers JE, Hu W, Gearing M, Glass JD (2016) Comparative analysis of C9orf72 and sporadic disease in an ALS clinic population. Neurology 87(10):1024–1030. https://doi.org/10.1212/WNL.0000000000003067
doi: 10.1212/WNL.0000000000003067
pubmed: 27488601
pmcid: 5027809
Knibb JA, Keren N, Kulka A, Leigh PN, Martin S, Shaw CE, Tsuda M, Al-Chalabi A (2016) A clinical tool for predicting survival in ALS. J Neurol Neurosurg Psychiatry 87(12):1361–1367. https://doi.org/10.1136/jnnp-2015-312908
doi: 10.1136/jnnp-2015-312908
pubmed: 27378085
pmcid: 5136716
Westeneng HJ, Debray TPA, Visser AE, van Eijk RPA, Rooney JPK, Calvo A, Martin S, McDermott CJ, Thompson AG, Pinto S, Kobeleva X, Rosenbohm A, Stubendorff B, Sommer H, Middelkoop BM, Dekker AM, van Vugt J, van Rheenen W, Vajda A, Heverin M, Kazoka M, Hollinger H, Gromicho M, Korner S, Ringer TM, Rodiger A, Gunkel A, Shaw CE, Bredenoord AL, van Es MA, Corcia P, Couratier P, Weber M, Grosskreutz J, Ludolph AC, Petri S, de Carvalho M, Van Damme P, Talbot K, Turner MR, Shaw PJ, Al-Chalabi A, Chio A, Hardiman O, Moons KGM, Veldink JH, van den Berg LH (2018) Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurol 17(5):423–433. https://doi.org/10.1016/S1474-4422(18)30089-9
doi: 10.1016/S1474-4422(18)30089-9
pubmed: 29598923
Li DW, Ren H, Jeromin A, Liu M, Shen D, Tai H, Ding Q, Li X, Cui L (2018) Diagnostic performance of neurofilaments in Chinese patients with amyotrophic lateral sclerosis: a prospective study. Front Neurol 9:726. https://doi.org/10.3389/fneur.2018.00726
doi: 10.3389/fneur.2018.00726
pubmed: 30210445
pmcid: 6121092
Steinacker P, Feneberg E, Weishaupt J, Brettschneider J, Tumani H, Andersen PM, von Arnim CA, Bohm S, Kassubek J, Kubisch C, Lule D, Muller HP, Muche R, Pinkhardt E, Oeckl P, Rosenbohm A, Anderl-Straub S, Volk AE, Weydt P, Ludolph AC, Otto M (2016) Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients. J Neurol Neurosurg Psychiatry 87(1):12–20. https://doi.org/10.1136/jnnp-2015-311387
doi: 10.1136/jnnp-2015-311387
pubmed: 26296871
Taga A, Maragakis NJ (2018) Current and emerging ALS biomarkers: utility and potential in clinical trials. Expert Rev Neurother 18(11):871–886. https://doi.org/10.1080/14737175.2018.1530987
doi: 10.1080/14737175.2018.1530987
pubmed: 30273061
Verber NS, Shepheard SR, Sassani M, McDonough HE, Moore SA, Alix JJP, Wilkinson ID, Jenkins TM, Shaw PJ (2019) Biomarkers in motor neuron disease: a state of the art review. Front Neurol 10:291. https://doi.org/10.3389/fneur.2019.00291
doi: 10.3389/fneur.2019.00291
pubmed: 31001186
pmcid: 6456669
Conti A, Riva N, Pesca M, Iannaccone S, Cannistraci CV, Corbo M, Previtali SC, Quattrini A, Alessio M (2014) Increased expression of Myosin binding protein H in the skeletal muscle of amyotrophic lateral sclerosis patients. Biochim Biophys Acta 1842(1):99–106. https://doi.org/10.1016/j.bbadis.2013.10.013
doi: 10.1016/j.bbadis.2013.10.013
pubmed: 24184715
Poesen K, Van Damme P (2018) Diagnostic and prognostic performance of neurofilaments in ALS. Front Neurol 9:1167. https://doi.org/10.3389/fneur.2018.01167
doi: 10.3389/fneur.2018.01167
pubmed: 30713520
Bacioglu M, Maia LF, Preische O, Schelle J, Apel A, Kaeser SA, Schweighauser M, Eninger T, Lambert M, Pilotto A, Shimshek DR, Neumann U, Kahle PJ, Staufenbiel M, Neumann M, Maetzler W, Kuhle J, Jucker M (2016) Neurofilament light chain in blood and CSF as marker of disease progression in mouse models and in neurodegenerative diseases. Neuron 91(2):494–496. https://doi.org/10.1016/j.neuron.2016.07.007
doi: 10.1016/j.neuron.2016.07.007
pubmed: 27477021
De Schaepdryver M, Jeromin A, Gille B, Claeys KG, Herbst V, Brix B, Van Damme P, Poesen K (2018) Comparison of elevated phosphorylated neurofilament heavy chains in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 89(4):367–373. https://doi.org/10.1136/jnnp-2017-316605
doi: 10.1136/jnnp-2017-316605
pubmed: 29054919
Poesen K, De Schaepdryver M, Stubendorff B, Gille B, Muckova P, Wendler S, Prell T, Ringer TM, Rhode H, Stevens O, Claeys KG, Couwelier G, D'Hondt A, Lamaire N, Tilkin P, Van Reijen D, Gourmaud S, Fedtke N, Heiling B, Rumpel M, Rodiger A, Gunkel A, Witte OW, Paquet C, Vandenberghe R, Grosskreutz J, Van Damme P (2017) Neurofilament markers for ALS correlate with extent of upper and lower motor neuron disease. Neurology 88(24):2302–2309. https://doi.org/10.1212/WNL.0000000000004029
doi: 10.1212/WNL.0000000000004029
pubmed: 28500227
Gille B, De Schaepdryver M, Goossens J, Dedeene L, De Vocht J, Oldoni E, Goris A, Van Den Bosch L, Depreitere B, Claeys KG, Tournoy J, Van Damme P, Poesen K (2019) Serum neurofilament light chain levels as a marker of upper motor neuron degeneration in patients with Amyotrophic Lateral Sclerosis. Neuropathol Appl Neurobiol 45(3):291–304. https://doi.org/10.1111/nan.12511
doi: 10.1111/nan.12511
pubmed: 29908069
Boylan KB, Glass JD, Crook JE, Yang C, Thomas CS, Desaro P, Johnston A, Overstreet K, Kelly C, Polak M, Shaw G (2013) Phosphorylated neurofilament heavy subunit (pNF-H) in peripheral blood and CSF as a potential prognostic biomarker in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 84(4):467–472. https://doi.org/10.1136/jnnp-2012-303768s
doi: 10.1136/jnnp-2012-303768s
pubmed: 23117489
Lu CH, Petzold A, Topping J, Allen K, Macdonald-Wallis C, Clarke J, Pearce N, Kuhle J, Giovannoni G, Fratta P, Sidle K, Fish M, Orrell R, Howard R, Greensmith L, Malaspina A (2015) Plasma neurofilament heavy chain levels and disease progression in amyotrophic lateral sclerosis: insights from a longitudinal study. J Neurol Neurosurg Psychiatry 86(5):565–573. https://doi.org/10.1136/jnnp-2014-307672
doi: 10.1136/jnnp-2014-307672
pubmed: 25009280
Gaiani A, Martinelli I, Bello L, Querin G, Puthenparampil M, Ruggero S, Toffanin E, Cagnin A, Briani C, Pegoraro E, Soraru G (2017) Diagnostic and prognostic biomarkers in amyotrophic lateral sclerosis: neurofilament light chain levels in definite subtypes of disease. JAMA Neurol 74(5):525–532. https://doi.org/10.1001/jamaneurol.2016.5398
doi: 10.1001/jamaneurol.2016.5398
pubmed: 28264096
pmcid: 5822207
Lu CH, Macdonald-Wallis C, Gray E, Pearce N, Petzold A, Norgren N, Giovannoni G, Fratta P, Sidle K, Fish M, Orrell R, Howard R, Talbot K, Greensmith L, Kuhle J, Turner MR, Malaspina A (2015) Neurofilament light chain: a prognostic biomarker in amyotrophic lateral sclerosis. Neurology 84(22):2247–2257. https://doi.org/10.1212/WNL.0000000000001642
doi: 10.1212/WNL.0000000000001642
pubmed: 25934855
pmcid: 4456658
Calvo A, Moglia C, Lunetta C, Marinou K, Ticozzi N, Ferrante GD, Scialo C, Soraru G, Trojsi F, Conte A, Falzone YM, Tortelli R, Russo M, Chio A, Sansone VA, Mora G, Silani V, Volanti P, Caponnetto C, Querin G, Monsurro MR, Sabatelli M, Riva N, Logroscino G, Messina S, Fini N, Mandrioli J (2017) Factors predicting survival in ALS: a multicenter Italian study. J Neurol 264(1):54–63. https://doi.org/10.1007/s00415-016-8313-y
doi: 10.1007/s00415-016-8313-y
pubmed: 27778156
Brooks BR, Miller RG, Swash M, Munsat TL (2000) El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 1(5):293–299
doi: 10.1080/146608200300079536
Schrooten M, Smetcoren C, Robberecht W, Van Damme P (2011) Benefit of the Awaji diagnostic algorithm for amyotrophic lateral sclerosis: a prospective study. Ann Neurol 70(1):79–83. https://doi.org/10.1002/ana.22380
doi: 10.1002/ana.22380
pubmed: 21437935
Riva N, Mora G, Soraru G, Lunetta C, Ferraro OE, Falzone Y, Leocani L, Fazio R, Comola M, Comi G (2019) Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Neurol 18(2):155–164. https://doi.org/10.1016/S1474-4422(18)30406-X
doi: 10.1016/S1474-4422(18)30406-X
pubmed: 30554828
Roche JC, Rojas-Garcia R, Scott KM, Scotton W, Ellis CE, Burman R, Wijesekera L, Turner MR, Leigh PN, Shaw CE, Al-Chalabi A (2012) A proposed staging system for amyotrophic lateral sclerosis. Brain 135(Pt 3):847–852. https://doi.org/10.1093/brain/awr351
doi: 10.1093/brain/awr351
pubmed: 22271664
pmcid: 3286327
Abrahams S, Newton J, Niven E, Foley J, Bak TH (2014) Screening for cognition and behaviour changes in ALS. Amyotroph Lateral Scler Frontotemporal Degener 15(1–2):9–14. https://doi.org/10.3109/21678421.2013.805784
doi: 10.3109/21678421.2013.805784
pubmed: 23781974
Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, van Swieten JC, Seelaar H, Dopper EG, Onyike CU, Hillis AE, Josephs KA, Boeve BF, Kertesz A, Seeley WW, Rankin KP, Johnson JK, Gorno-Tempini ML, Rosen H, Prioleau-Latham CE, Lee A, Kipps CM, Lillo P, Piguet O, Rohrer JD, Rossor MN, Warren JD, Fox NC, Galasko D, Salmon DP, Black SE, Mesulam M, Weintraub S, Dickerson BC, Diehl-Schmid J, Pasquier F, Deramecourt V, Lebert F, Pijnenburg Y, Chow TW, Manes F, Grafman J, Cappa SF, Freedman M, Grossman M, Miller BL (2011) Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 134(Pt 9):2456–2477. https://doi.org/10.1093/brain/awr179
doi: 10.1093/brain/awr179
pubmed: 21810890
pmcid: 3170532
Strong MJ, Abrahams S, Goldstein LH, Woolley S, McLaughlin P, Snowden J, Mioshi E, Roberts-South A, Benatar M, HortobaGyi T, Rosenfeld J, Silani V, Ince PG, Turner MR (2017) Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): revised diagnostic criteria. Amyotroph Lateral Scler Frontotemporal Degener 18(3–4):153–174. https://doi.org/10.1080/21678421.2016.1267768
doi: 10.1080/21678421.2016.1267768
pubmed: 28054827
Riva N, Falini A, Inuggi A, Gonzalez-Rosa JJ, Amadio S, Cerri F, Fazio R, Del Carro U, Comola M, Comi G, Leocani L (2012) Cortical activation to voluntary movement in amyotrophic lateral sclerosis is related to corticospinal damage: electrophysiological evidence. Clin Neurophysiol 123(8):1586–1592. https://doi.org/10.1016/j.clinph.2011.12.013
doi: 10.1016/j.clinph.2011.12.013
pubmed: 22326728
de Carvalho M, Chio A, Dengler R, Hecht M, Weber M, Swash M (2005) Neurophysiological measures in amyotrophic lateral sclerosis: markers of progression in clinical trials. Amyotroph Lateral Scler Other Motor Neuron Disord 6(1):17–28. https://doi.org/10.1080/14660820410020600
doi: 10.1080/14660820410020600
pubmed: 16036422
Gendron TF, Group CONS, Daughrity LM, Heckman MG, Diehl NN, Wuu J, Miller TM, Pastor P, Trojanowski JQ, Grossman M, Berry JD, Hu WT, Ratti A, Benatar M, Silani V, Glass JD, Floeter MK, Jeromin A, Boylan KB, Petrucelli L (2017) Phosphorylated neurofilament heavy chain: a biomarker of survival for C9ORF72-associated amyotrophic lateral sclerosis. Ann. Neurol 82(1):139–146. https://doi.org/10.1002/ana.24980
doi: 10.1002/ana.24980
pubmed: 28628244
pmcid: 5676468
Agosta F, Ferraro PM, Riva N, Spinelli EG, Domi T, Carrera P, Copetti M, Falzone Y, Ferrari M, Lunetta C, Comi G, Falini A, Quattrini A, Filippi M (2017) Structural and functional brain signatures of C9orf72 in motor neuron disease. Neurobiol Aging 57:206–219. https://doi.org/10.1016/j.neurobiolaging.2017.05.024
doi: 10.1016/j.neurobiolaging.2017.05.024
pubmed: 28666709
Menke RA, Gray E, Lu CH, Kuhle J, Talbot K, Malaspina A, Turner MR (2015) CSF neurofilament light chain reflects corticospinal tract degeneration in ALS. Ann Clin Transl Neurol 2(7):748–755. https://doi.org/10.1002/acn3.212
doi: 10.1002/acn3.212
pubmed: 26273687
pmcid: 4531057
Thouvenot E, Demattei C, Lehmann S, Maceski-Maleska A, Hirtz C, Juntas-Morales R, Pageot N, Esselin F, Alphandery S, Vincent T, Camu W (2019) Serum neurofilament light chain at time of diagnosis is an independent prognostic factor of survival in amyotrophic lateral sclerosis. Eur J Neurol. https://doi.org/10.1111/ene.14063
doi: 10.1111/ene.14063
pubmed: 31437330
Li S, Ren Y, Zhu W, Yang F, Zhang X, Huang X (2016) Phosphorylated neurofilament heavy chain levels in paired plasma and CSF of amyotrophic lateral sclerosis. J Neurol Sci 367:269–274. https://doi.org/10.1016/j.jns.2016.05.062
doi: 10.1016/j.jns.2016.05.062
pubmed: 27423602
Ganesalingam J, An J, Shaw CE, Shaw G, Lacomis D, Bowser R (2011) Combination of neurofilament heavy chain and complement C3 as CSF biomarkers for ALS. J Neurochem 117(3):528–537. https://doi.org/10.1111/j.1471-4159.2011.07224.x
doi: 10.1111/j.1471-4159.2011.07224.x
pubmed: 21418221
pmcid: 3076545